Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
Turn Therapeutics published peer-reviewed research in the journal Life demonstrating that its lead candidate GX-03 selectively reduced key inflammatory drivers in a murine dermatitis model. Pretreatment with GX-03 reduced IL-36 by approximately 50% and IL-31 by nearly 68%, resulting in a 66% reduction in clinical dermatitis severity compared to controls.
Key figures
- Il4 reduction pct
- 16.7
- Il31 reduction pct
- 67.7
- Viga score treated
- 0.83
- Viga score untreated
- 2.44
- Il36 alpha reduction pct
- 49.9
- Il36 gamma reduction pct
- 50.9
- Clinical severity reduction pct
- 66
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.